

References

Alberg AJ, Singh S., et al. Epidemiology of the breast cancer in older women: implications for future healthcare. *Drug Aging*; 18:761-772, 2001.

Andrei Iagraru, Rinat Maseamed, et al. Breast MRI and 18F FDG PET/CT in the management of breast cancer. *Annals of Nuclear Medicine*. Vol. 21; No. 1, Pag: 33–38, 2007.

Antoch G, Saoudi N, Kuchl H, et al. Accuracy of whole-Body dual-modality, fluorine-18-2-fluoro-2deoxy-D-glucose positron emission tomography(FDG-PET/CT) for tumor staging in solid tumors: Comparison with CT and PET. *J Clin Oncol*; 22:4357-4368, 2004.

Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. *J Clin Oncol*; 18: 3495-3502, 2000.

Aysegul A. Sahin, Pathology of the invasive breast cancer. *Breast Cancer*, 2nd edition, chapter 13, page198-216, BC Decker Inc, Hamilton, 2006.

Bakheet SM, Powe J, Kandil A, et al. F-18 FDG uptake in breast infection and inflammation. *Clin Nucl Med*; 25:100–103, 2000.

Barbara Zangheri, Cristina Messa, Maria Picchio, et al. PET/CT and breast cancer. *Eur. J.Nucl. Med. Mol. Imaging*; 31, Suppl. 1:135–142, 2004.

Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. *J Nucl Med*; 44:1200-1209, 2003.

Bellamy C.O.C., McDonald C., Salter D .M., et al. Non invasive ductal carcinoma of the breast: The relevance of histological categorization. Human Pathology; 24: 1 6-20, 1993.

Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med; 41:1369-1379, 2000.

Beyer T, Watson CC, Meltzer CC, et al. The Biograph: a premium dual-modality PET/CT tomograph for clinical oncology. Electromedica; 69:120-126, 2001.

Blodgett T Beyer T, Antoch G, et al.: Dual modality PET/CT imaging: The effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging; 30: 588-596, 2003.

Biersack HJ, Palmedo H; Locally advanced breast cancer: is PET useful for monitoring primary chemotherapy? Journal Nuclear Medicine; 44:1815–1817, 2003.

Biersack HJ, Bender H, Palmedo H: FDG-PET in monitoring therapy of breast cancer. Eur J Nucl Med Mol Imaging; Suppl. 1:S112-S117, 2004.

Brinton L, Lacey J, Deversa S. et al. Epidemiology of breast cancer . In Cancer of the Breast, 5th edition, edited by Donegan W, Spratt J, WB Saunders, and Ch.27:111-131, 2002.

Brown M, Eccles C, and Wallis MG., et al. Geographical distribution of breast cancers on the mammogram: an interval cancer database. The British Journal of Radiology; 74:317-322, 2001.

Cachin F,Prince HM, Hogg A,et al. Powerful prognostic stratification by fluorodeoxyglucose positron emission tomography in patients with

metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol;24(19):3026–3031, 2006.

Carkaci S, Macapinlac HA, Cristofanilli M, et al. Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data: Journal of nuclear medicine ;(abstract) , 2009.

Chinyama CN,Davies JD., et al. Mammary mucinous lesions: prevalence and important pathological associations, Histopathology; 29:533-539, 1996.

Cohade C, Osman M, Nakamoto Y, et al. Initial experience with oral contrast in PET/CT, Phantom and clinical studies. J Nucl Med; 44: 412-416, 2003.

Cook GJ, Houston S, Rubens R, et al. Detection of Bone Metastases in Breast Cancer by 18FDG PET: Differing Metabolic Activity in Osteoblastic and Osteolytic Lesions, Japan Journal of Oncology; 16:3375-3379, 2007.

Cotran R.S, Kumar V. And Collins T. et al. Pathologic basis of disease (6th edition. The breast. WB Saunders, Philadelphia; 1094-1119, 1999

C. MESSA, V.BETTINARDI, M.PICCHIO, et al., PET/CT in diagnostic oncology: Q J NUCL MED MOL IMAGING; 48:66-75, 2004.

David R. Brenin, Kristen A. Atkins. et al., Unusual breast histology, Breast Cancer, 2nd edition, chapter 24 ,page 405-419, Bc Decker inc, Hamilton, 2006.

David P. Winchester, Staging and Histologic Grading, Breast Cancer, 2nd edition, chapter 14, page 217-225, BC Decker Inc, Hamilton, 2006.

David Yeung, Nathan Yeung, Thomas Cheng, et al; Improving diagnosis of primary breast carcinoma in FDG PET/CT scan using lesion to contralateral nipple maximum standardized uptake value (SUVmax) ratio; J Nucl Med.; 47 (Supplement 1):437P, 2006.

Delgado RC., Carreras JL., the Roles of PET and CT/PET as Preoperative Studies, IV, Madrid Breast Cancer Conference. (2005)

Diane M. Wolinski, Director, North Florida Cyclotron Center, LLC PET/CT in Radiation Oncology: The FROG Manual for Clinical Use, Radioisotopes 2nd Edition; (1-76), 2006.

Dizendorf EV, E, Hany TF, Buck A, et al. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med; 44:30–32, 2003.

Dose J, Bleckmann C, Bachmann S, et al. Comparison of fluorodeoxyglucose positron emission tomography and “conventional diagnostic procedures” for the detection of distant metastases in breast cancer patients. Nucl Med Commun; 23: 857–864, 2002.

Edward C. Klatt, The internet pathology laboratory for medical education, Florida State University of Medicine, 2006.

Emilio Bombardieri, Cumali Aktolun, Richard P. Baum, et al. FDG-PET-Procedures Guidelines For Tumour Imaging European Association of Nuclear Medicine September 2, 2003.

Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small-cell lung cancer using positron emission tomography (PET). Radiother Oncol; 62:51–60, 2002.

Eric L. Rosen, William B. Eubank, David A. Mankoff, et al. FDG PET, PET/CT, and Breast Cancer Imaging; Monitoring Response to Therapy with FDG PET and PET/CT Neoadjuvant Systemic Therapy in LABC. *RadioGraphics*; 27:S215–S229, 2007.

Eubank WB, Mankoff DA, Takasugi J, et al. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. *J Clin Oncol*; 19:3516-3523, 2001.

Eubank WB, Mankoff D, Bhattacharya M, et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. *AJR Am J Roentgenol*; 183(2): 479–486, 2004.

Fueger BJ, Weber WA, Quon A, et al. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. *Mol Imaging Biol.*; 7:369–376, 2005.

Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. *Invest Radiol*; 38:250–256, 2003.

Grahek D, Montravers F, Kerrou K, et al. [18 F] FDG in Recurrent Breast Cancer: Diagnostic Performances, Clinical Impact and Relevance of Induced Changes in Management. *European Journal of Nuclear Medicine*; 31:179-188, 2007.

Gutzeit A, Antoch G, Kuhl H, et al. Unknown primary tumors: Detection with dual – modality PET/CT – initial experience. *Radiology*; 234:227-234, 2005.

Hany TF, Steinert HC, Goerres GW, et al: PET diagnostic accuracy improvement with in – line PET/CT system: Initial results. Radiology; 225: 575-581, 2002.

Harris J.R, Lippman M.E, Osborne C.K. et al. Diseases of the breast (4 Th edition). Diagnosis and management of benign breast diseases. Philadelphia. JB Lippincott; 81-82, 2002.

Harvey, Unusual breast cancers, Radiology: Volume 242: Number 3, page 684-694, March 2007.

Helen Krontiars, Kirby I. Bland, et al. Anatomy of the breast, Axilla, and Thoracic wall, Breast Cancer, 2nd edition, chapter 2, page 15-30, Bc Decker inc, Hamilton, 2006.

Henry T. Lynch, Jane F.Lynch., et al. Genetics, Natural History, and DNA-Based Genetic Counseling In Hereditary Breast Cancer, Breast Cancer, 2nd edition, Chapter 5, page 5-81, Bc Decker inc, Hamilton, 2006.

Heusner TA, Kuemmel S, Umutlu L, et al Breast cancer staging in a single session: whole-body PET/CT mammography: Journal of nuclear medicine Aug; 49(8):1215-1222.,Epub 2008.

Hicks RJ, Binns D, Stabin MG, et al. Pattern of uptake and excretion of (18)F-FDG in the lactating breast. J Nucl Med; 42:1238–1242, 2001.

Hima B. Prabhakar, Dushyant V. Sahani, Alan J. Fischman, et al. Bowel Hot Spots at PET/CT, RSNA, RadioGraphics; 27: 145-159, 2007.

Holland R and Hendriks JH., et al. Microcalcifications associated with DCIS: Mammographic-pathologic correlation. Semin Diag. Pathol: 11; 181-192, 1997.

Hoon Hee Park, Sei Young Kim, Jae Sam Kim, et al. Utility of prone position on PET/CT in breast cancer (Abstract), J Nucl Med.; 49 (Supplement 1):425P, 2008.

[http:// www.medicineworld.org](http://www.medicineworld.org), 2008.

[http:// www.cancerline.com](http://www.cancerline.com), 2007.

[http:// www.zoladex.net](http://www.zoladex.net), 2008.

[http:// www.imaginis.com](http://www.imaginis.com),2007

Hyo Soon Lim, Woong Yoon, Tae Woong Chung, et al. FDG PET/CT for the Detection and Evaluation of Breast Diseases: Usefulness and Limitations; RadioGraphics; 27:S197–S213, 2007.

Ilknur AK, Stokkel MP and Pauwels EK, et al. Positron Emission Tomography with 2-(18F) Fluoro-2-deoxy-D-Glucose in oncology, part 2: The clinical value in detecting and staging primary tumours. J Cancer Res Cli Oncol; 126: 560-574, 2000.

Janet Cochrane , Susanna I., et al. Radiology Rounds, Massachusetts General Hospital; volume 2:issue 5, 2004.

Jemal A,Tiwari RC,Murray T. et al. Cancer statistics, CA Cancer J Clin ; 54:8-29, 2004..

Kapoor Vibhu, Barry M and Frank S, et al. An introduction to PET/CT imaging, Radiographics; 24: 523-543, 2004.**Kopans DB**, Pathologic, mammographic and sonographic correlation. In: Kopans D.B., ed. Breast imaging, 2nd ed., Lippincott Raven Publishers, Philadilphia, p.511-615, 1998.

Korn RL, Yost AM, May CC, et al. Unexpected focal hypermetabolic activity in the breast: significance in patients undergoing 18F-FDG PET/CT. *AJR Am J Roentgenol*; 187:81–85, 2006.

Kostakoglu L, Agress H, Goldsmith SJ, et al. Clinical role of FDG PET in Evaluation of Cancer Patients, *RSNA, RadioGraphics*; 23:315-340, 2003.

Kumar R, Alavi A., et al. Fluorodeoxyglucose-PET in the management of breast cancer; *Radiol Clin North Am*; 42:1113–1122, 2004.

Kumar R, Chauhan A, Zhuang H, et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. *Breast Cancer Res Treat*; 98: 267–274, 2006.

Lale Kostakoglu, Ruth Hardoff, Rosna Mirtcheva, et al. PET-CT Fusion Imaging in Differentiating Physiologic from Pathologic FDG Uptake *RadioGraphics*; Volume 24; Number 5:1411–1431, RSNA, 2004.

Landis K. Griffeth, Use of PET/CT scanning in cancer patients: technical and practical considerations *Proc (Bayl Univ Med Cent)*; 18(4): 321–330, October 2005.

Lardiniois D, Weder W, Hany TF, et al. staging of non- small-cell lung cancer with integrated positron emission tomography and computed tomography. *N Engl J Med.*; 348:2500-2507, 2003.

Lea Radan, Simona Ben-Haim, Rachel Bar-Shalom, et al. The Role of FDG-PET/CT in Suspected Recurrence of Breast Cancer: *Cancer*; 107: number (11); pag 2545–2551. American Cancer Society, 2006.

Lloyd J, Flanagan AM. Mammary and extramammary Paget's disease. *J. Clin. Pathol.*; 53:742-749, 2000.

Malcolm R. Kell, Monica Morrow, et al. Multifocal, Multicentric, and Bilateral breast cancer, Breast Cancer, 2nd edition, chapter 25 ,page 420-431, Bc Decker inc, Hamilton, 2006.

Mamede M, Higashi T, Kitaichi M., et al: (18F) FDG uptake and PCNA, Glut-1 And Hexokinase-II expressions in cancers and inflammatory lesions of the lung neoplasia; 7: 369-379, 2005.

Mawlawi O, Pan T, Cody DD et al. Evaluation of a new CT truncation correction algorithm for accurate quantification of PET/CT images. J Nucl Med; 45: P161&P 413, 2004.

Mayo Clinic: Mayo Foundation for Medical Education and Research. <http://www.Mayo Clinic .com/ medical services/cancer treatment>, 2006.

Mitsuhiro Hayashi, Koji Murakami, Testsunari Oyama, et al. PET/CT supports breast cancer diagnosis and treatment, new trends in breast diagnostic imaging. Breast Cancer; 15:224–230 the Japanese Breast Cancer Society, 2008.

Naveen Subhas, Pavni V. Patel, Harpreet K. Pannu, et al. Imaging of Pelvic Malignancies with In-Line FDG PET–CT: Case Examples and Common Pitfalls of FDG PET; RadioGraphics; 25:1031–1043, 2005.

Nathan C Hall, Stephen P Povoski, Douglas A Murrey, et al. Combined approach of perioperative ¹⁸F-FDG PET/CT imaging and intraoperative ¹⁸F-FDG handheld gamma probe detection for tumor localization and verification of complete tumor resection in breast cancer. Jr World J Surg Oncol.; 5 : 143 .World Journal of Surgical Oncology , 2007.

Omar Sh., Genevieve Contesso, et al. Breast cancer. Fourth edition. Association of Medicales Franco-Egyptienne: ch.6, pag: 67-75, 2001.

Osborne MP., Breast anatomy and development, Diseases of the breast. 2nd edition .Philadelphia :Lippincott, Williams and Wilkins, pp: 1-14, 2000.

Osman MM, Cohade C, Nakamoto Y, et al. Respiratory motion artifacts On PET emission images obtained using CT attenuation correction on PET/CT, Eur J Nucl Med Mol Imaging; 30: 603-606, 2003.

Peter L. Williams, Breast anatomy Integumental system, Gray's Anatomy 38th edition; page: 417-424, 1995.

Peter S. Conti, Daniel k. Cam, et al. PET-CT A Case-Based Approach; pt 1 p4-8, 2005.

Ramsey I., Pathology of malignant neoplasm. In: Mitchell G.I.V. and Bassett L.W., Eds. The female breast and its disorders. Williams and Wilkins, New York. 1990.

82-***Richard L. Drake, Wayne Yogi, Adam W. M Mitchell, ET al.*** Anatomy for students, 2005.

Rohren EM, Turkington TG, Coleman ER, et al. Clinical applications of PET in oncology, Radiographics; 23: 305-332, 2004.

Rose C, Dose J, Avril N, et al. Positron emission tomography for the diagnosis of breast cancer. Nucl Med Community; 23:613-618, 2002.

Rosen P., Rosen's breast pathology, 2nd edition, Lippincott Williams& Wilkins, Philadelphia, pp: 3-6, 32-34, 2001.

RC Delgado-Bolton, JL Carreras Delgado, et al. The roles of PET and CT/PET as preoperative studies. Breast Cancer Research; volume 7 (Suppl 1):S7, 2005.

References

- Schirrmeister H, Kuhn T, Guhlmann A, et al.*** Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. *Eur J Nucl Med*; 28:351-358, 2001.
- Schwartz G.F., Finkel G.C., Garcia J.C., et al.*** Subclinical ductal carcinoma in situ of the breast:70; 246, 1992.
- Schwarz JD, Bader M, Jenicke L, et al.*** Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. *J Nucl Med.*; 46:1144–1150, 2005.
- Scott L. Spear, John W. Little, William C. Wood, et al.,*** *Surgery of the Breast, principles and Art*, 1998.
- Shigeto Ueda, Hitoshi Tsu, Hideki Asak, et al.*** Clinicopathological and Prognostic Relevance of Uptake Level using (18F-FDG PET/CT) in Primary Breast Cancer, *Japanese journal of clinical oncology Jpn J Clin Oncol.*; 38,(4):250–258, 2008.
- Shimoda W, Hayashi M, Murakami K, et al.*** The relationship between FDG uptake in PET scans and biological behavior in breast cancer. *Breast Cancer*; 14:260–268, 2007.
- Smith IC, Welch AE, Hutcheon AW, et al.*** Positron emission tomography using [18F]- fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. *Journal Clinical Oncology*; 18:1676-1688, 2000.
- S. T.Treves.,*** *Pediatric Nuclear Medicine/PET. Third Edition*; 18:490-497, 2007.

Suga K, Okada M, Yuan Y, et al., Breast Sentinel Lymph Node Mapping at CT Lymphography with Iopamidol: Preliminary Experience, *Radiology*; 230:543-552, 2004.

Tatsumi Mitsuaki, Christian Cohade, Karen A. Mourtzikos, et al. Initial experience with FDG-PET/CT in the evaluation of breast cancer. *Eur J Nucl Med Mol Imaging (European Journal of Nuclear Medicine and Molecular Imaging)*; Vol.33, No 3, Pag: 254–262, 2006

Thompson CJ. Instrumentation. In: Burk ed. , *Principles and practice of PET*. Philadelphia, Pa: Lippincott; 48-63, 2002.

Thomas Beyer, Gerald Antoch, Stefan Müller, et al. Acquisition protocol considerations for combined PET/CT imaging .*J Nucl Med*; 45:25S-35S, 2004.

Todd M. Blodgett, Melanie B. Fukui, Carl H. Snyderman, et al. Combined PET-CT in the Head and Neck Part 1. Physiologic, Altered Physiologic and Artifactual FDG Uptake, *RadioGraphics*; 25:897–912, 2005.

Todd M. Blodgett, Carolyn C. Meltzer, David W. Townsend, et al PET/CT: Form and Function *Radiology*. Breast cancer; Volume 242: Number 2; 360–385, RSNA, 2007.

Uematsu T, Yuen S, Yukisawa S, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. *AJR Am J Roentgenol*; 184:1266-1273, 2005

Victor G. Vogel, *Breast Cancer* ,2nd edition, Chapter 4,Epidemiology Of Breast cancer; page48-50, Bc Decker inc, Hamilton, 2006.

Visvikis D, Costa DC, Croasdale I, et al. CT-based attenuation correction in the calculation of semi-quantitative indices of (18F) FDG uptake in PET. Eur J Nucl Med; 30:344-353, 2003.

Von Schulthess GK, Steinert HC, Hany TF, et al. Integrated PET/CT: Current applications and Future directions. Radiology; 238: 405-442, 2006.

Vranjesevic D, Schiepers C, Silverman DH, et al. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med; 44:1238–1242, 2003

Wei-Jen Yao, Tsai-Wang Chang, Pin-Wen Lin, et al. F-18-FDG PET/CT in staging of locally advanced breast cancer. J Nucl Med.; 48 (Supplement 2):143P, 2007.

Woo Hee Choi, Je Ryung Yoo, Sung Hoon Kim, et al. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients. J Nucl Med.; 48 (Supplement 2): 138-369P, 2007.

W F Eddie Lau, David S Binns, Robert E Ware, et al. Clinical experience with the first combined positron emission tomography/ computed tomography scanner in Australia MJA;182(4):172-176, 2005.

Yang S., Cho N. and Moon W., et al. The Role of PET/CT for Evaluating Breast Cancer, Korean Journal of Radiology; 8:429-437, October 2007.

Yefremov N, Guralnik L, Gaitini D, et al. Clinical performance of PET/CT In evaluation of cancer: Additional value for diagnosis imaging and patient management. J Nucl Med; 44: 1200-1209, 2003.